抗苗勒管激素作为多囊卵巢综合征诊断标志物的系统评价与荟萃分析
该系统评价纳入45项研究,比较血清抗苗勒管激素(AMH)与血清雄激素及经阴道/经腹部超声对多囊卵巢综合征(PCOS)的诊断价值。病例对照研究荟萃分析显示敏感度81%、特异度82%,横断面研究显示敏感度80%、特异度85%,证据确定性评为「低」。结论认为AMH在考虑年龄、检测标准化、PCOS表型和体质指数等因素时可作为诊断标志物,否则应作为共识和/或指南诊断标准的辅助。
要点
- 病例对照研究荟萃分析:AMH诊断PCOS敏感度81%、特异度82%(95%CI未报告)。
- 横断面研究荟萃分析:AMH诊断PCOS敏感度80%、特异度85%(95%CI未报告)。
- 证据确定性评为「低」,AMH需考虑年龄、检测标准化、表型和体质指数等因素。
核心结论
- 血清AMH水平在考虑年龄、检测标准化、PCOS表型和体质指数等因素时可作为PCOS的诊断标志物。
- 否则,AMH应作为通过共识和/或指南建立的PCOS诊断标准的辅助。
- 此外,血清AMH浓度反映了该综合征的严重程度。
研究设计与样本
- 系统文献综述与荟萃分析,检索Cochrane Library、Embase、LILACS、PubMed、Scopus、Web of Science和Google Scholar数据库。
- 纳入截至2023年8月以任何语言发表的人体研究,仅限使用Rotterdam(2003)、美国国立卫生研究院(1990)、雄激素过多与PCOS学会或2013、2018、2023年循证指南诊断PCOS的研究。
- 共纳入45项研究,两名独立评审者筛选文献并提取分析数据。
- 使用QUADAS-2和GRADE工作组工具分析偏倚风险和证据确定性。
主要发现
- 研究在「参考标准」和「流程与时间」领域为低偏倚风险,「患者选择」领域为中等偏倚风险,「指数试验」领域为高偏倚风险。
- 病例对照研究的荟萃分析显示敏感度81%、特异度82%(95%CI未报告)。
- 横断面研究的荟萃分析显示敏感度80%、特异度85%(95%CI未报告)。
- 证据确定性评为「低」。
关键数值与推荐
- 病例对照研究荟萃分析:敏感度81%、特异度82%。
- 横断面研究荟萃分析:敏感度80%、特异度85%。
- 证据确定性评为「低」。
临床怎么用
- 作者认为,在考虑年龄、检测标准化、PCOS表型和体质指数等因素时,血清AMH水平可作为PCOS的诊断标志物。
- 作者认为,否则AMH应作为通过共识和/或指南建立的PCOS诊断标准的辅助。
- 作者指出,血清AMH浓度反映了该综合征的严重程度。
局限性
- 研究在「患者选择」领域为中等偏倚风险,在「指数试验」领域为高偏倚风险。
- 证据确定性评为「低」。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether serum anti-Müllerian hormone measurement can be used as a diagnostic marker for polycystic ovary syndrome compared to serum androgen measurement and transvaginal/transabdominal ultrasound. DATA SOURCES: A systematic literature review and meta-analysis were conducted. Electronic and manual searches were carried out in the Cochrane Library, Embase, Latin American and Caribbean Health Sciences Literature (LILACS), PubMed, Scopus, Web of Science, and Google Scholar databases. STUDY ELIGIBILITY CRITERIA: Studies conducted in humans, published in any language up to August 2023, and addressing the following research question were included: "Can serum anti-Müllerian hormone levels be used as a diagnostic marker of polycystic ovary syndrome in comparison to serum androgen levels and transvaginal/transabdominal ultrasound?" Furthermore, only articles that used the Rotterdam (2003) criteria, the National Institutes of Health (1990) criteria, the Androgen Excess and Polycystic Ovary Syndrome Society criteria, or the Evidence-based Guidelines on polycystic ovary syndrome from 2013, 2018, and 2023 for diagnosing women with polycystic ovary syndrome were included. STUDY APPRAISAL AND SYNTHESIS METHODS: Two independent reviewers selected the studies and extracted and analyzed the data. The Quality Assessment of Diagnostic Accuracy Studies-2 and Grades of Recommendation, Assessment, Development, and Evaluation Working Group tools were used to analyze the risk of bias and certainty of evidence. RESULTS: This systematic review included 45 studies. The studies exhibited a low risk of bias in the "Reference standard" and "Flow and time" domains but showed a moderate risk of bias in the "Patient selection" domain and a high risk of bias in the "Index test" domain. The meta-analysis of the case-control studies demonstrated a sensitivity of 81% and specificity of 82%, whereas the meta-analysis of the cross-sectional studies showed a sensitivity of 80% and specificity of 85%, both with 95% confidence intervals. The certainty of the evidence was rated as "low." CONCLUSION: This systematic review showed that serum anti-Müllerian hormone levels can serve as a diagnostic marker for polycystic ovary syndrome when factors such as age, test standardization, polycystic ovary syndrome phenotypes, and body mass index are considered. Otherwise, anti-Müllerian hormone should be used as an adjuvant to the polycystic ovary syndrome diagnostic criteria established through consensus and/or guidelines. Additionally, serum concentrations reflected the severity of this syndrome.
引用
- Gomes MO, Gomes JO, Ananias LF, et al. Anti-Müllerian hormone as a diagnostic marker of polycystic ovary syndrome: a systematic review with meta-analysis. Am J Obstet Gynecol. 2025. PMID: 39922442. doi:10.1016/j.ajog.2025.01.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。